Alexander Semaan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander Semaan has a total of 321 co-authors. Here are the top co-authors by number of shared publications:
Bret M. Stephens
Sheikh Ahmed Pancreatic Cancer Research Center The University of Texas MD Anderson Cancer Center Houston TX USA
68 shared publicationsAnirban Maitra
Sheikh Ahmed Pancreatic Cancer Research Center The University of Texas MD Anderson Cancer Center Houston TX USA
67 shared publicationsPaola A. Guerrero
Sheikh Ahmed Pancreatic Cancer Research Center The University of Texas MD Anderson Cancer Center Houston TX USA
63 shared publications- Cullen M. Taniguchi
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
50 shared publications - Jaewon James Lee
Department of Surgery, University of North Carolina, Chapel Hill, NC, USA
43 shared publications - Vincent Bernard
Department of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
41 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8736
AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins
Experimental validation and functional optimization remain bottlenecks in AI-based protein design. We present a scalable workflow for developing AI-designed minibinders against cancer-associated surface proteins. Screening thousands of designs using mammalian cell-surface display identifies several high-affinity PD-L1 minibinders but far fewer for CD276 (B7-H3) and VTCN1 (B7-H4), highlighting substantial target dependence. Interface predicted template modeling (ipTM) scores generated by Chai-1 with ESM embeddings correlate with binding success and capture deleterious effects of interface mutations. Fluorophore-labeled AI-minibinders enable flow-cytometric staining comparable to conventional antibodies. However, when incorporated into chimeric antigen receptors (CAR), some show poor cell-surface trafficking and limited functionality. Redesign through a genetic algorithm-based diversification strategy that preserves the binding interface while changing non-binding surfaces experimentally reveals an isoelectric point (pI) window that improves CAR expression and enhances target-selective tumor cell killing. Our findings identify biochemical optimization beyond the binding interface as a critical requirement for translating AI-minibinders into functional applications.
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8736
Open AccessAI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins
Experimental validation and functional optimization remain bottlenecks in AI-based protein design. We present a scalable workflow for developing AI-designed minibinders against cancer-associated surface proteins. Screening thousands of designs using mammalian cell-surface display identifies several high-affinity PD-L1 minibinders but far fewer for CD276 (B7-H3) and VTCN1 (B7-H4), highlighting substantial target dependence. Interface predicted template modeling (ipTM) scores generated by Chai-1 with ESM embeddings correlate with binding success and capture deleterious effects of interface mutations. Fluorophore-labeled AI-minibinders enable flow-cytometric staining comparable to conventional antibodies. However, when incorporated into chimeric antigen receptors (CAR), some show poor cell-surface trafficking and limited functionality. Redesign through a genetic algorithm-based diversification strategy that preserves the binding interface while changing non-binding surfaces experimentally reveals an isoelectric point (pI) window that improves CAR expression and enhances target-selective tumor cell killing. Our findings identify biochemical optimization beyond the binding interface as a critical requirement for translating AI-minibinders into functional applications.
- Open Access
- 22 February 2026
- Published by Wiley in Molecular Oncology
- Vol. 20 (7) , 1762-1779
Pre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies
Liquid biopsies enable noninvasive tumor profiling and longitudinal disease monitoring. Their analytical performance is strongly influenced by pre‐analytical factors, yet direct comparisons between cell‐free DNA (cfDNA) and extracellular vesicle‐derived DNA (evDNA) remain scarce. We prospectively evaluated four pre‐analytical variables: processing delay, storage temperature, tube type, and plasma input volume, on cfDNA and evDNA from cancer patient plasma ( n = 244) using ddPCR, Qubit, and TapeStation. Key findings were validated in archived plasma samples ( n = 723). In the prospective cohort, cfDNA concentrations increased after 24 h and evDNA after 48 h at room temperature, while retrospective analysis revealed earlier changes (cfDNA: 6 h; evDNA: 24 h). Storage conditions influenced both analytes, as short‐term refrigeration (4 °C) better preserved DNA quality than −80 °C freezing, while extracted DNA remained stable at −80 °C. Acid citrate dextrose (ACD) and K 2 EDTA tubes performed similarly under prompt processing. Higher plasma volumes improved evDNA, but not cfDNA, for mutation detection. evDNA demonstrates greater resilience than cfDNA under suboptimal conditions. Standardized workflows and prompt processing are essential to ensure reliable mutation detection in clinical liquid biopsy applications.
- 22 February 2026
- Published by Wiley in Molecular Oncology
- Vol. 20 (7) , 1762-1779
Open AccessPre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies
Liquid biopsies enable noninvasive tumor profiling and longitudinal disease monitoring. Their analytical performance is strongly influenced by pre‐analytical factors, yet direct comparisons between cell‐free DNA (cfDNA) and extracellular vesicle‐derived DNA (evDNA) remain scarce. We prospectively evaluated four pre‐analytical variables: processing delay, storage temperature, tube type, and plasma input volume, on cfDNA and evDNA from cancer patient plasma ( n = 244) using ddPCR, Qubit, and TapeStation. Key findings were validated in archived plasma samples ( n = 723). In the prospective cohort, cfDNA concentrations increased after 24 h and evDNA after 48 h at room temperature, while retrospective analysis revealed earlier changes (cfDNA: 6 h; evDNA: 24 h). Storage conditions influenced both analytes, as short‐term refrigeration (4 °C) better preserved DNA quality than −80 °C freezing, while extracted DNA remained stable at −80 °C. Acid citrate dextrose (ACD) and K 2 EDTA tubes performed similarly under prompt processing. Higher plasma volumes improved evDNA, but not cfDNA, for mutation detection. evDNA demonstrates greater resilience than cfDNA under suboptimal conditions. Standardized workflows and prompt processing are essential to ensure reliable mutation detection in clinical liquid biopsy applications.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Parental tumor localization of cholangiocarcinoma (CC) PDO cultures.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Parental tumor localization of cholangiocarcinoma (CC) PDO cultures.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Expression of CK7 and CA19-9 via immunohistochemistry (IHC) in PDO cultures.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Expression of CK7 and CA19-9 via immunohistochemistry (IHC) in PDO cultures.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Complete and incomplete expression patterns of Her2 and Her3 in cholangiocarcinoma.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Complete and incomplete expression patterns of Her2 and Her3 in cholangiocarcinoma.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
TCGA cholangiocarcinoma cohort survival analysis. Overall survival analysis with respect to gene expression of Her2 (ERBB2), Trop2 (TACSTD2), Her3 (ERBB3), folate receptor 1 (FOLR1), and Nectin4 (PVRL4) in TCGA Bile Duct Cancer (CHOL) dataset (36 primary tumor).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
TCGA cholangiocarcinoma cohort survival analysis. Overall survival analysis with respect to gene expression of Her2 (ERBB2), Trop2 (TACSTD2), Her3 (ERBB3), folate receptor 1 (FOLR1), and Nectin4 (PVRL4) in TCGA Bile Duct Cancer (CHOL) dataset (36 primary tumor).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
HER2/HER3 IHC scoring criteria following gastric cancer guidelines. A table listing the definition and interpretation of the HER2 and HER3 IHC scoring system.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
HER2/HER3 IHC scoring criteria following gastric cancer guidelines. A table listing the definition and interpretation of the HER2 and HER3 IHC scoring system.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Intratumoral heterogeneity of Trop2 expression in a cholangiocarcinoma tissue microarray (TMA).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Intratumoral heterogeneity of Trop2 expression in a cholangiocarcinoma tissue microarray (TMA).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Organoid culture media protocol.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Organoid culture media protocol.